JP2021512159A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021512159A5 JP2021512159A5 JP2020561952A JP2020561952A JP2021512159A5 JP 2021512159 A5 JP2021512159 A5 JP 2021512159A5 JP 2020561952 A JP2020561952 A JP 2020561952A JP 2020561952 A JP2020561952 A JP 2020561952A JP 2021512159 A5 JP2021512159 A5 JP 2021512159A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- fragment
- sequence
- fusion protein
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 26
- 108020001507 fusion proteins Proteins 0.000 claims 16
- 102000037865 fusion proteins Human genes 0.000 claims 16
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims 12
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims 11
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 10
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 10
- 229920001184 polypeptide Polymers 0.000 claims 10
- 239000012634 fragment Substances 0.000 claims 7
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 4
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 4
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 4
- 210000004899 c-terminal region Anatomy 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 3
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 230000008499 blood brain barrier function Effects 0.000 claims 3
- 210000001218 blood-brain barrier Anatomy 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 230000002238 attenuated effect Effects 0.000 claims 1
- 230000008827 biological function Effects 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 230000006870 function Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023094278A JP2023123535A (ja) | 2017-01-30 | 2023-06-07 | 血液脳関門移動化合物及びその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762452015P | 2017-01-30 | 2017-01-30 | |
| US201762530980P | 2017-07-11 | 2017-07-11 | |
| IBPCT/IB2018/050576 | 2018-01-30 | ||
| PCT/IB2018/050576 WO2018138709A1 (en) | 2017-01-30 | 2018-01-30 | Blood-brain barrier transmigrating compounds and uses thereof |
| PCT/IB2018/055747 WO2019150183A1 (en) | 2017-01-30 | 2018-07-31 | Blood-brain barrier transmigrating compounds and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023094278A Division JP2023123535A (ja) | 2017-01-30 | 2023-06-07 | 血液脳関門移動化合物及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021512159A JP2021512159A (ja) | 2021-05-13 |
| JP2021512159A5 true JP2021512159A5 (https=) | 2021-09-09 |
| JP7458327B2 JP7458327B2 (ja) | 2024-03-29 |
Family
ID=62977950
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019541280A Active JP7449092B2 (ja) | 2017-01-30 | 2018-01-30 | 血液脳関門移動化合物及びその使用 |
| JP2020561952A Active JP7458327B2 (ja) | 2017-01-30 | 2018-07-31 | 血液脳関門移動化合物及びその使用 |
| JP2023094278A Pending JP2023123535A (ja) | 2017-01-30 | 2023-06-07 | 血液脳関門移動化合物及びその使用 |
| JP2024031648A Pending JP2024081644A (ja) | 2017-01-30 | 2024-03-01 | 血液脳関門移動化合物及びその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019541280A Active JP7449092B2 (ja) | 2017-01-30 | 2018-01-30 | 血液脳関門移動化合物及びその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023094278A Pending JP2023123535A (ja) | 2017-01-30 | 2023-06-07 | 血液脳関門移動化合物及びその使用 |
| JP2024031648A Pending JP2024081644A (ja) | 2017-01-30 | 2024-03-01 | 血液脳関門移動化合物及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US11702466B2 (https=) |
| EP (2) | EP3574002A4 (https=) |
| JP (4) | JP7449092B2 (https=) |
| KR (3) | KR20240095466A (https=) |
| CN (2) | CN110382522B (https=) |
| AU (4) | AU2018212860A1 (https=) |
| CA (2) | CA3052058A1 (https=) |
| WO (2) | WO2018138709A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240095466A (ko) * | 2017-01-30 | 2024-06-25 | 내션얼 리서치 카운슬 오브 캐나다 | 혈액-뇌 장벽을 관통이동하는 화합물 및 이의 용도 |
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| CN113508135A (zh) * | 2018-10-29 | 2021-10-15 | 比奥根Ma公司 | 增强血脑屏障转运的人源化和稳定化的fc5变体 |
| AU2020214796A1 (en) | 2019-01-30 | 2021-07-29 | Truebinding, Inc. | Anti-Gal3 antibodies and uses thereof |
| EP4058479A4 (en) * | 2019-11-15 | 2024-02-28 | University of Tennessee Research Foundation | MODIFIED IMMUNOLOBULINES FOR TARGETING AMYLOID DEPOSITS |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| JP2024519488A (ja) * | 2021-05-05 | 2024-05-14 | ユニバーシティ オブ テネシー リサーチ ファウンデーション | アミロイド疾患を治療するためのペプチド－ｆｃ融合体 |
| JP2024521082A (ja) * | 2021-05-18 | 2024-05-28 | ユニバーシティ オブ テネシー リサーチ ファウンデーション | アミロイド障害を処置するための抗体－ペプチド融合タンパク質 |
| KR102475326B1 (ko) * | 2022-01-27 | 2022-12-07 | 한국기초과학지원연구원 | 신규한 펩타이드 유사체 및 이를 포함하는 알츠하이머 병 예방 조성물 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5385915A (en) | 1990-05-16 | 1995-01-31 | The Rockefeller University | Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation |
| DE69434520T3 (de) | 1993-07-30 | 2009-10-15 | Affymax, Inc., Palo Alto | Biotinylierung von proteinen |
| AU2001263006A1 (en) | 2000-05-18 | 2001-11-26 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| US7943129B2 (en) * | 2000-05-26 | 2011-05-17 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
| WO2001090190A2 (en) * | 2000-05-26 | 2001-11-29 | National Research Council Of Canada | Single-domain antigen-binding antibody fragments derived from llama antibodies |
| WO2002086122A2 (en) | 2001-03-14 | 2002-10-31 | Hybrigenics | Protein-protein interactions in adipocytes |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| JP2003135075A (ja) * | 2001-11-05 | 2003-05-13 | Research Association For Biotechnology | 新規な全長ｃＤＮＡ |
| NZ532838A (en) | 2001-11-30 | 2008-05-30 | Ca Nat Research Council | Multimeric complex preferably pentamer molecules derived from the AB5 toxin family i.e. verotoxin and their use in medical treatment |
| EP1452601A1 (en) | 2003-02-28 | 2004-09-01 | Roche Diagnostics GmbH | Enhanced expression of fusion polypeptides with a biotinylation tag |
| CA2562833A1 (en) * | 2004-04-27 | 2005-11-03 | Galapagos N.V. | Methods, agents, and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts |
| DE602006008460D1 (de) * | 2005-06-17 | 2009-09-24 | Ca Nat Research Council | NEUES Aß-BINDUNGSPROTEIN UND DESSEN PEPTIDDERIVATE SOWIE VERWENDUNGEN DAVON |
| US20090047300A1 (en) | 2005-09-27 | 2009-02-19 | Abedelnasser Abulrob | Blood-brain barrier epitopes and uses thereof |
| TW200907056A (en) * | 2007-03-28 | 2009-02-16 | Astrazeneca Ab | New method |
| US8986689B2 (en) | 2010-04-14 | 2015-03-24 | National Research Council Of Canada | Compositions and methods for brain delivery of analgesic peptides |
| US20110269735A1 (en) * | 2010-04-19 | 2011-11-03 | Celera Corporation | Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof |
| PL2621955T3 (pl) | 2010-10-01 | 2018-07-31 | National Research Council Of Canada | Przeciwciała anty-CEACAM6 i ich zastosowania |
| MX350378B (es) | 2012-01-10 | 2017-09-05 | Biogen Ma Inc | Mejora del transporte de moleculas terapeuticas a traves de la barrera hematoencefalica. |
| RU2711552C2 (ru) * | 2012-08-29 | 2020-01-17 | Ф. Хоффманн-Ля Рош Аг | Шаттл для гематоэнцефалического барьера |
| UA120047C2 (uk) | 2014-03-06 | 2019-09-25 | Нешнл Рісеч Каунсіл Оф Канада | Антигензв'язуючий фрагмент антитіла, який специфічно зв'язується з рецептором інсуліноподібного фактора росту 1 (igf1r) |
| PE20170088A1 (es) | 2014-03-06 | 2017-03-09 | Nat Res Council Canada | Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos |
| PE20161311A1 (es) | 2014-03-06 | 2016-11-25 | Nat Res Council Canada | Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos. |
| WO2016097315A2 (en) * | 2014-12-19 | 2016-06-23 | Medimmune Limited | Blood brain barrier transport molecules and uses thereof |
| US20200231652A1 (en) * | 2015-08-31 | 2020-07-23 | National Research Council Of Canada | Tgf-b-receptor ectodomain fusion molecules and uses thereof |
| BR112019000220A2 (pt) * | 2016-07-06 | 2019-04-24 | National Research Council Of Canada | anticorpos humanizados que transmigram a barreira hematoencefálica e usos dos mesmos |
| EP3551666A4 (en) | 2016-12-12 | 2020-07-29 | National Research Council of Canada | VARIANTS OF ANTIBODIES CROSSING THE HEMATOENCEPHALIC BARRIER AND THEIR USES |
| KR20240095466A (ko) | 2017-01-30 | 2024-06-25 | 내션얼 리서치 카운슬 오브 캐나다 | 혈액-뇌 장벽을 관통이동하는 화합물 및 이의 용도 |
-
2018
- 2018-01-30 KR KR1020247019801A patent/KR20240095466A/ko active Pending
- 2018-01-30 CN CN201880015949.5A patent/CN110382522B/zh active Active
- 2018-01-30 WO PCT/IB2018/050576 patent/WO2018138709A1/en not_active Ceased
- 2018-01-30 US US16/481,898 patent/US11702466B2/en active Active
- 2018-01-30 JP JP2019541280A patent/JP7449092B2/ja active Active
- 2018-01-30 CA CA3052058A patent/CA3052058A1/en active Pending
- 2018-01-30 KR KR1020197025302A patent/KR102676279B1/ko active Active
- 2018-01-30 AU AU2018212860A patent/AU2018212860A1/en not_active Abandoned
- 2018-01-30 EP EP18745446.7A patent/EP3574002A4/en active Pending
- 2018-07-31 AU AU2018405992A patent/AU2018405992A1/en not_active Abandoned
- 2018-07-31 CN CN201880091218.9A patent/CN111886240A/zh active Pending
- 2018-07-31 JP JP2020561952A patent/JP7458327B2/ja active Active
- 2018-07-31 WO PCT/IB2018/055747 patent/WO2019150183A1/en not_active Ceased
- 2018-07-31 CA CA3089816A patent/CA3089816A1/en active Pending
- 2018-07-31 EP EP18904229.4A patent/EP3746460A4/en active Pending
- 2018-07-31 KR KR1020207025008A patent/KR20200116143A/ko not_active Ceased
- 2018-07-31 US US16/965,885 patent/US20230257424A1/en not_active Abandoned
-
2022
- 2022-03-23 AU AU2022202015A patent/AU2022202015B2/en active Active
-
2023
- 2023-03-14 US US18/183,812 patent/US20230279088A1/en active Pending
- 2023-06-07 JP JP2023094278A patent/JP2023123535A/ja active Pending
-
2024
- 2024-03-01 JP JP2024031648A patent/JP2024081644A/ja active Pending
- 2024-03-20 AU AU2024201813A patent/AU2024201813A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021512159A5 (https=) | ||
| US20240076370A1 (en) | Antibodies targeting g-protein coupled receptor and methods of use | |
| US12343401B2 (en) | Modular self assembly disassembly (SADA) technologies | |
| CN112646031B (zh) | 抗4-1bb纳米抗体及其用途 | |
| US10899835B2 (en) | IgM Fc and J-chain mutations that affect IgM serum half-life | |
| KR102501921B1 (ko) | 유도성 결합 단백질 및 사용 방법 | |
| RU2558301C2 (ru) | Полипептиды для связывания с "рецептором конечных продуктов гликирования", а также их композиции и способы, в которых они принимают участие | |
| RU2663349C2 (ru) | Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний | |
| JP5911821B2 (ja) | 受容体チロシンキナーゼａｌｋの細胞外ドメインに結合する抗体 | |
| KR20190134997A (ko) | 항-tau 항체 및 이의 사용 방법 | |
| JP2017529067A (ja) | Ｃｄ３結合ドメイン | |
| JP2020124203A (ja) | 血液脳関門輸送分子およびそれらの使用 | |
| JP2017537082A5 (https=) | ||
| KR20230104229A (ko) | Cd3에 결합하는 폴리펩티드 구축물 | |
| KR20230098335A (ko) | 클리핑 비율이 감소된 항원 결합 도메인 | |
| CA3160855A1 (en) | Antibodies targeting cell surface deposited complement protein c3d and use thereof | |
| HK40122548A (zh) | 抗cd44v6抗体及其用於治疗cd44v6过表达癌症的用途 | |
| EP2319871A1 (en) | Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same | |
| EP2308896A1 (en) | Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same |